Treatment of type 2 diabetes mellitus: A weighty enigma

Annals of Internal Medicine

Volumn 143, Issue 8, 2005, Pages 609-610

  Comi, Richard J ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; EXENDIN 4; GASTROINTESTINAL HORMONE; GLUCOSE; INCRETIN; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; PEPTIDE; UNCLASSIFIED DRUG;

BEHAVIOR MODIFICATION; CLINICAL TRIAL; COUGHING; DIETARY INTAKE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LIFESTYLE; LUNG DISEASE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT FAILURE; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; NOTE;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; LIFE STYLE; OBESITY;

EID: 26944475537     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-143-8-200510180-00012     Document Type: Review

References (10)

1. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimaUy controlled type 2 diabetes. A randomized trial. Ann Intern Med. 2005;143:559-69.
2. Rosenstock J, Zinman B, Murphy LJ, Clement SC, Moore P, Bowering CK, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes. A randomized, controlled trial. Ann Intern Med. 2005;143:549-58.
3. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004;287:E199-206. [PMID: 15271645]
4. Drucker DJ. Glucagon-like peptides. Diabetes. 1998;47:159-69. [PMID: 9519708]
5. Bloomgarden ZT. Gut-derived incretin hormones and new therapeutic approaches. Diabetes Care. 2004;27:2554-9. [PMID: 15451935]
6. Freemantle N, Blonde L, Duhot D, Hompesch M, Eggertsen R, Hobbs FD, et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care. 2005;28:427-8. [PMID: 15677807]
7. Cefalu WT, Skyler JS, Kourides IA, Landschulz WH, Balagtas CC, Cheng S, et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med. 2001;134:203-7. [PMID: 11177333]
8. Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, et al. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care. 2004;27:2356-62. [PMID: 15451900]
9. Abrahamson MJ. Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context. Arch Intern Med. 2004;164:486-91. [PMID: 15006824]
10. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev. 1998;19:477-90. [PMID: 9715376]